Comparative Pharmacology
Head-to-head clinical analysis: DESMOPRESSIN ACETATE PRESERVATIVE FREE versus NOCTIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMOPRESSIN ACETATE PRESERVATIVE FREE versus NOCTIVA.
DESMOPRESSIN ACETATE PRESERVATIVE FREE vs NOCTIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic analog of antidiuretic hormone (ADH, vasopressin) that binds to V2 receptors in renal collecting ducts, increasing water permeability and reabsorption, thereby reducing urine volume and increasing urine osmolality. Also increases factor VIII and von Willebrand factor levels via V2 receptor activation on endothelial cells.
Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that binds to V2 receptors in the renal collecting ducts, increasing water reabsorption and reducing urine volume.
0.2-0.4 mg (200-400 mcg) orally once daily at bedtime, or 0.1-0.2 mg (100-200 mcg) orally two to three times daily. Alternatively, 1-4 mcg (0.001-0.004 mg) intravenously or subcutaneously once daily.
Desmopressin acetate: 1-2 sprays (10-20 mcg) intranasally once daily at bedtime; or 0.1-0.2 mg orally once daily at bedtime.
None Documented
None Documented
1.5-2.5 hours (terminal elimination half-life); prolonged in renal impairment (up to 5-6 hours in severe renal failure).
Terminal elimination half-life is 2-4 hours (mean 3.2 hours) in adults with normal renal function; prolonged to 6-9 hours in moderate renal impairment (CrCl 30-50 mL/min).
Primarily renal (filtration and tubular secretion); approximately 60-70% of the administered dose is excreted unchanged in urine; minor biliary/fecal elimination (<5%).
Renal excretion of unchanged drug accounts for approximately 70% of the dose; fecal elimination constitutes about 20%, with the remainder as metabolites.
Category A/B
Category C
Vasopressin Analog
Vasopressin Analog